Dec 5 2018
8:00 AM

Linda Pissott Reig, shareholder and co-chair of the firm's FDA & Biotechnology practice, presented at and was co-chair of the BioNJ Legal, Compliance and Regulatory Forum.

The panel discussed implications of patient engagement and key considerations, including:

  • applicable statuses and cases that help define legal risk
  • recent government actions that impact how risk is assessed, managed and minimized
  • ongoing demand for greater transparency in pharmaceutical and biotech relationships
  • longstanding expectation that industry support of patient organizations is done in a manner that preserves the organization's independence